ARQ 197
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cirrhosis
Conditions
Cirrhosis, Hepatocellular Carcinoma
Trial Timeline
Jan 1, 2009 โ Dec 1, 2011
NCT ID
NCT00802555About ARQ 197
ARQ 197 is a phase 1 stage product being developed by Merck for Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00802555. Target conditions include Cirrhosis, Hepatocellular Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00802555 | Phase 1 | Completed |
| NCT00658554 | Phase 1 | Completed |
| NCT00612703 | Phase 1 | Completed |
| NCT00557609 | Phase 2 | Completed |
| NCT00612209 | Phase 1 | Completed |
| NCT00302172 | Phase 1 | Completed |
Competing Products
20 competing products in Cirrhosis